Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acelrx Pharmaceutica (ACRX)

Acelrx Pharmaceutica (ACRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,338
  • Shares Outstanding, K 79,573
  • Annual Sales, $ 2,150 K
  • Annual Income, $ -47,150 K
  • 60-Month Beta 2.11
  • Price/Sales 49.16
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.25
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.48 +4.73%
on 02/20/20
1.85 -16.22%
on 01/22/20
-0.26 (-14.36%)
since 01/21/20
3-Month
1.48 +4.73%
on 02/20/20
2.50 -38.00%
on 12/11/19
-0.11 (-6.63%)
since 11/21/19
52-Week
1.48 +4.73%
on 02/20/20
4.09 -62.10%
on 03/05/19
-1.71 (-52.45%)
since 02/21/19

Most Recent Stories

More News
AcelRx Pharmaceuticals (ACRX) Stock Moves -1.14%: What You Should Know

In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.73, marking a -1.14% move from the previous day.

ACRX : 1.55 (-3.73%)
AcelRx Pharmaceuticals (ACRX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, AcelRx Pharmaceuticals (ACRX) closed at $1.91, marking a -0.78% move from the previous day.

ACRX : 1.55 (-3.73%)
AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today...

ACRX : 1.55 (-3.73%)
Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

CORT : 13.59 (-0.51%)
PCRX : 48.49 (-3.06%)
ACRX : 1.55 (-3.73%)
SLNO : 3.19 (-3.92%)
Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA

The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).

CORT : 13.59 (-0.51%)
ACRX : 1.55 (-3.73%)
XON : 4.65 (-4.12%)
ASRT : 1.31 (-2.24%)
Catalyst Gives Preliminary Firdapse Estimates & Other Updates

Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.

CPRX : 5.21 (+0.19%)
CORT : 13.59 (-0.51%)
ACRX : 1.55 (-3.73%)
ASRT : 1.31 (-2.24%)
Have Faith in Rising P/E: Play 5 Top-Ranked Stocks

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

BKH : 84.73 (-0.06%)
GTLS : 68.23 (+1.25%)
ACRX : 1.55 (-3.73%)
DNKN : 76.08 (-0.34%)
DYNT : 0.95 (unch)
AcelRx Pharmaceuticals (ACRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ACRX : 1.55 (-3.73%)
Jazz Enrolls First Patient in Phase II/III Leukemia Study

Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

INVA : 15.12 (+0.13%)
JAZZ : 134.82 (-0.50%)
ACRX : 1.55 (-3.73%)
GH : 88.81 (+1.59%)
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M

Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.

ACRX : 1.55 (-3.73%)
IRWD : 11.63 (-3.16%)
ASRT : 1.31 (-2.24%)
JNCE : 5.28 (-7.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ACRX with:

Business Summary

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and...

See More

Key Turning Points

2nd Resistance Point 1.66
1st Resistance Point 1.61
Last Price 1.55
1st Support Level 1.52
2nd Support Level 1.48

See More

52-Week High 4.09
Fibonacci 61.8% 3.09
Fibonacci 50% 2.79
Fibonacci 38.2% 2.48
Last Price 1.55
52-Week Low 1.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar